PROJECT NARRATIVE The goal in this application is to determine the efficacy of PG545 to synergize with PARP inhibitors in vivo using PDX models and in patient derived ascitic cells and to confirm whether the underlying mechanism by which PG545 downregulates RAD51 in ovarian cancer cells.
|Effective start/end date||2/1/22 → 1/31/23|
- National Cancer Institute: $185,831.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.